We have analyzed published platelet time series in four normal individuals and 29 putative cyclical thrombocytopenia patients for evidence of significant (p 5 0.05) cyclicity. Three of the normal individuals (all males) showed significant cycling (periods T of 23, 30 and 31 days) as did 15 of the cyclical thrombocytopenia patients (T from 13 to 65 days). Cyclical thrombocytopenia seems to be approximately equally prevalent in women and men, though in cases where a definite etiology was suggested an autoimmune origin occurs more frequently in women. We also briefly review the current state of knowledge of the control of platelet production by thrombopoietin (c-Mpl ligand) and previous attempts that have been made to construct mathematical models for the platelet control system.
INTRODUCTION
Periodic hematological diseases are unusual and fascinating in that the numbers of one or more of the circulating blood cells (red cells, white cells, platelets) spontaneously oscillate with periods on the order of days to months Haurie et al. (1998) . They are classical examples of dynamical diseases [Glass and Mackey (1988) l. In some of these diseases, such as cyclical neutropenia [Haurie et al. (1999a [Haurie et al. ( ,b, 1998 ; Haurie and Mackey (1999) ; Heam et al. (1998) l and periodic chronic myelogenous leukemia [Fortin and Mackey (1999) ], there is clear evidence for statistically significant cycling of all of the major blood cell groups with the same period in a given subject. It is generally thought that these disorders involve a destabilization at the pluripotential stem cell (PPSC) level such that there is an oscillatory efflux of cells into all differentiation pathways [Mackey (1978 [Mackey ( , 1979a [Mackey ( , 1996 l. In other dynamic hematological diseases like periodic auto-immune hemolytic anemia [BClair et al. (1995) ; Kirk et ul. 'Corresponding Author: Tel: (514) Fax: (5 14) 398-7452; E-mail: mackey@cnd.mcglll.ca; 3655 Drummond Street, Room 1 124, Montreal, Quebec, CANADA H3G 1Y6 (1968) ; Mackey (1979b) ; Mahaffy et al. (1998); Orr et al. (1968) l there is an oscillation in only one of the major blood cell types. Cyclical thrombocytopenia (CT) is a rare blood disease apparently falling into this second category.
Cyclical thrornbocytopenia is characterized by a periodic rise and fall in circulating platelet counts, generally from normal to below normal values. This disease is associated with a number of bleeding symptoms which have no apparent origin other than the thrombocytopenia. Cyclical thrombocytopenia, like periodic auto-immune hemolytic anemia, probably involves a destabilization of a single peripheral control loop mediated by one or more circulating cytokine regulators.
Cyclic thrombocytopenia has been previously reported with periods between 20 and 40 days [Aranda and Dorantes (1977) ; Balduini et al. (1993) ; Bernard and Caen (1962) Cohen and Cooney (1974) . It has also been reported that oscillations could be detected in the platelet counts of normal individuals with the same range of periods [Morley (1969); von Schulthess and Gessner (1986) 
We have identified 29 clinical reports of putative cyclical thrornbocytopenia and four reports of platelet cycling in normal individuals. Using techniques developed in astrophysics for the detection of statistically significant periodicity in unevenly sampled data, we have examined these clinical studies to determine the nature of platelet cycling in normals and in cyclical thrombocytopenia. Following a review of platelet production and control and cyclical thrornbocytopenia in Section 2, and a brief description of our data selection criteria and analysis methods in Section 3, we present our main results in Section 4. The paper concludes with a brief discussion in Section 5.
THROMBOPOIESIS AND CYCLICAL THROMBOCYTOPENIA

Platelet Production and Control
Platelets are important for the body's clotting response to injury as well as day to day blood vessel repair. The mechanism of platelet formation is complex and not fully understood. Platelets arise from large megakaryocytes found in the bone marrow, which are derived from pluripotential hematopoietic stem cells. (1995) . The iinrmture rnegakaryocyte has a large nucleuc that occupies most of the cell volume. As the nucleus increases its ploidy, the cytoplasmic portion of the polyploid megakaryocyte expands. With the cytoplasmic expansion comes the development of the smooth, internal demarcation membrane system that will eventually become the external membrane of each platelet. Once the demarcation membrane is in place, membrane-bound sections of cytoplasm are pinched off from the megakaryocyte in sausage-like links termed pro-platelets [Beutler et al. (1995) l. One mature megakaryocyte can give rise to between 1000 and 5000 platelets [Beutler rt al. (199511. The primary cytolune responsible for platelet formation, thrombopoietin (TPO), was discovered in 1994 to be the ligand for the c-Mpl receptor, the cellular homologue of the viral oncogene for myeloproliferative leukemia [Eaton and de Sauvage (1 997); Kaushansky (I 995); Papayannopoulou (1996) l. Thrombopoietin stimulates hematopoietic stem cells to enter the cell cycle from their dormant Go phase [Ritchie etal. (1996) l. TPO also stimulates proliferation and differentiation of megakaryocyte precursors [Tanimukai et al. (1997) ], decreases precursor apoptosis [Borge et al. (1996 [Borge et al. ( , 1997 ; Ratajczak et al. (1997) ; Ritchie et al. (1996 Ritchie et al. ( , 1997 ; Zauli et al. (1997) ], promotes megakaryocyte maturation [Eaton and de Sauvage (1997) ; Kaushansky et al. ( 1 995)], increases megakaryocyte ploidy [Kuter et al. (1997) l and ~timulates the release of platelets via the fragmentation of mature megakaryocytes [Kuter (1996) l. The effects of TPO can be enhanced when combined with other cytokines [Zeigler et al. (l994) l. These effects of TPO qualitatively mimic the effects of erythropoietin and granulocyte colony stimulating factor in the erythroid and granulocytic lines respectively. Whereas originally it was thought that the effects of thrombopoietin were limited to cells of the megakaryocyte lineage, it is now known that in addition TPO plays a role in myelopoiesis and erythropoiesis and acts on both lineage committed cells and on immature, pluripotential stem cells [Sitnicka et al. (1996) ; Solar et al. (1998) 
Other cytokines associated with platelet production can be classified into two categories: early acting factors whose effects are widespread, and late acting factors that are specific to the megakaryocyte lineage [Kaushansky (1995) l. The early acting factors, which include interlukin-3 (11-3), the c-kit ligand [KL, also termed stem cell factor (SCF) or steel factor (SF)], and GM-CSF (granulocyte-macrophage colony stimulating factor), are megakaryocyte colony stimulating factors (Meg-CSF's). They are megakaryocyte proliferation factors and their effect is to expand the pool of megakaryocyte-specific hematopoietic progenitors J. Late acting factors do not promote megakaryocyte colony formation.
They do, however stimulate megakaryocyte differentiation and maturation. Late acting factors include Interlukin 6 and I I (11-6 and 11-1 1) and leukemia inhibitory factor (LIF) [Broudy and Kaushansky (1995) l. TPO is thus both an early and a late acting factor in megakaryocyte differentiation l.
Human platelet levels remain relatively stable for years unless perturbed by disease or pregnancy [Kuter et al. (1997) l. Between species or between individuals within a species, however, platelet counts vary. The normal range for human platelet level is 150-450 x lo9 plateletsL blood with an average of 290 x lo9 plateletsk. The body tightly regulates platelet mass and not platelet number. TPO plays an important role in this regulatory process [Kuter ( l996)I.
Cyclical Thrombocytopenia
In cyclical thrombocytopenia, platelet counts oscillate from very low (1 x lo9 plateletsk blood) to normal (150-450 x 1 0~1~) or very high levels (2000 x 1 0~1~) .
In addition, patients may exhibit one or several of the following symptoms: purpura, petechiae, epistaxis, gingival bleeding, menorrhagia, easy bruising, possibly premensturally, and gastrointestinal bleeding. The period of the platelet oscillation varies between individuals, and has been reported in many cases to be approximately monthly [Kimura et al. (1996) ; Helleberg et a1. (1995) ; Yanabu et a/. (1993) ; Bernard and Caen (196211. In some female patients platelet cycles are reported to be in phase with the menstrual cycle [Tomer et al. (1989) ; Helleberg et al. (1995) ], while other investigators report no correlation with the menstrual cycle [Yanabu et al. (1993); ; Menitove et al. (1989) l. One group reported that the platelet oscillations were in phase with the patient's menstrual cycle when this was controlled by exogenous hormone therapy, but not in phase with the patient's natural menstrual cycle [Cohen and Cooney (1974) l.
There are two proposed origins of cyclical thrombocytopenia. One is an auto-immune origin most prevalent in females. The other is of amegakaryocytic origin, most common in males.
Autoimmmune cyclical thrornbocytopenia is postulated to be an unusual form of immune thrombocytopenic purpura (ITP) [Beutler et al. (1995) l. In this type of cyclical thrombocytopenia, antiplatelet autoantibodies periodically remove large numbers of platelets from the circulation. The antibodies attack platelet membrane-bound glycoproteins GPIIb/IIIa and, to a lesser extent GPIbIIX, which are specific to platelets. GPIIbIIIIa is the receptor for fibinogen and is essential for clot formation and is thus abundant on platelet membranes. Several investigators [Kimura et al. (1996) ; Helleberg et 01. (1995) : Yanabu et al. (1993) ; Menitove e t a / . (1989)l have reported cycles of platelet-associated immunoglobin G(PA1gC) reciprocal to the fluctuations of platelets. There is no explanation for the production of the autoant~bodies. Tomer et a1. (1989) reported an increase in the expression of macrophage Fcy receptors near the onset of thrombocytopenia. They suggest that the Fcy receptor is in part responsible for the clearance of antibody-coated platelets. Autoimmune cyclical thrombocytopenia is characterized by a shortened platelet life span at the time of decreasing platelet counts [Beutler et a1. (1995) l which is consistent with an increase in platelet destruction, high levels of antiplatelet autoantibodies and normal to high levels of bone marrow megakaryocytes. In this type of cyclical thrombocytopenia the platelet oscillations are thought to be due to a cyclical destruction of platelets.
The second type of cyclical thrombocytopenia has a different etiology. In the amegakaryocytic variety platelet oscillations are thought to be due to a cyclical failure in platelet production [Bernard and Caen (1962) ; Cohen and Cooney (1974) ; Dan et al. (1991) ; Engstrom et al. (1966); Hoffman et al. (1989) : Lewis (1974) l. This variety is characterized by oscillations in bone marrow megakaryocytes preceding the platelet oscillations [Balduini et al. (1993) ; Bernard and Caen (1962) ; Dan et al. (1991) ; Engstrom et al. (1966) l. Platelet life span is generally normal [Lewis (1974) l and antibodies against platelets are not detected l. It is possible that the failure of platelet production could arise at the stern cell level since in at least one case [Kimura et al. (1996) I there were parallel cycles of erythrocytes exactly out of phase with the megakaryocyte cycles. It is thought, however, that in the majority of patients the cycling is at the megakaryocyte level [Dan et al. (1991) ; Hoffman et al.
(1 989)l. Kimura et al. (1996) suggest that a cyclical fluctuation in the level of various cytokines is responsible for the oscillations in platelet counts. This group postulates that the fluctuation in cytokines leads to both cyclical platelet production and cyclical platelet destruction and thus both types of CT are involved simultaneously. It is known that plasma concentrations of c-Mpl ligand are inversely proportional to circulating platelet numbers [Kuter and Rosenberg (1995) : Kuter (1996) l just as the circulating levels of granulocyte colony stimulating factor (G-CSF) are inversely proportional to circulating levels of granulocytes [Layton et al. (1989) l. It has been suggested for both G-CSF [Layton et al. (1989) l and c-Mpl [Kuter (1996) l ligand that their levels are regulated by the mass of their primary cellular population targets (granulocytes and platelets respectively).
DATA AND METHODS
We identified 33 sets of serial platelet counts published by 23 groups of investigators between 1962 and 1996 in which oscillations in platelet counts of normal individuals or cyclical thrombocytopenia were claimed to exist. Of these, four sets were reported in Goldschmidt and Fono (1972) , three each in Morley (1969) and Cohen and Cooney (1974) , two by each of Rocha et al. (199 l) , Dan et al. (1991), von Schulthess and Gessner (1986) , and Wilkinson and Firkin (1966) , and one in each of Kimura et a1. (1996) , Helleberg et a1. (1995) , Kosugi et al. (1994) , Yanabu et 01. (1993) , Balduini et al. (1993) Caen et ul. (1964) , and Bernard and Caen (1962) . Each data set was scanned using Photoshop 4.0 and digitized using Ghostview 2.2 to convert the published platelet counts into a uniform, digitized format for analysis of the period of the oscillations.
The Lomb periodogram, an extension of the Fourier power spectral technique for unevenly sampled data, was used to detect periodicity in each data set. Specifically, let y, be the concentration of platelets as measured at times t,, where j = For any given time series, if the null hypothesis is that the values yJ are independent Gaussian random noise, and that P ( T ) has an exponential probability distribution with unit mean, the significance level (p value) of any peak in that time series is given by where 1Z. l x N [Press et al. (1 992)l.
We implemented Equation 2 for a set of different periods T. The estimation of the significance level of P(T) in any given set of platelet counts is straightforward as long as some criteria are satisfied for the choice of the range and the number of periods that are scanned [Fortin and Mackey (1999) ; Press et al. (1992) ; Scargle (1982) l. An individual data set was considered periodic if the significance level p of the principal peak in the periodogram satisfies p 5 0.05 (5%), though the question of significance when multiple time series are analyzed needs further consideration (see the Discussion). An adaptation of the procedure proposed in Press et al. (1992) , using Matlab, was used to analyze the digitized data (cf. [Fortin and Mackey (1999) ; Haurie et al. (1999a, b) ] for more details).
RESULTS
We initially considered all 33 data sets that we found in the published literature. Based on our criterion for statistical significance ( p _< 0.05), 15 of these sets were discarded. Thus, of the 33 data sets, 18 were selected for final analysis. Of the 18, nine were from female subjects and nine were from males. Table I gives a summary of each study, the period of the oscillations, and the corresponding significance level of the individual time series. Our results are also displayed graphically in Figures I and 2 for females and males respectively.
The period of the platelet oscillations, as determined by the periodogram analysis, was 28 & 15 days in the women subjects, and varied from a minimum of 13 days in the female subject of Menitove et ul. (1 989) to a maximum of 65 days in the female subject from . For the males the period was 34 f 6 days with a range of 26 [Goldschmidt and Fono (1972) l to 43 days [Engstrom TABLE I A summary of the periodicties (in days) estimated through periodograrn analysis with each of their significance levels, when the significance levels p 5 0.05, for the normal individuals and cyclical thrombocytopenia patients identified in this study. A1 indicates autoimmune, AM amegakaryocytic, CCHF denotes cyanotic congenital heart failure and C-TPO stands for cycling TPO levels. (1966) l. We noted that, on average, the periods of the oscillations in the auto-immune type data (range from 13 to 36 days) were shorter than the period of the amegakaryocytic CT data which ranged from 27 to 65 days. Although there were insufficient numbers of data sets to draw firm statistically significant conclusions, this observation will be an interesting line to investigate. There was no apparent correlation between the period of the platelet oscillation, the mean platelet count, or the amplitude of the platelet oscillation.
In five of the nine female subjects, the investigators claimed an auto-immune origin for the disease. One female case appeared to be amegakaryocytic. One child had cyclical thrombocytopenia associated with cyanotic congenital heart disease. In five of the male subjects an amegakaryocytic origin was implicated, one had cyanotic congenital heart disease, and three were healthy. Morley (1969) von Schulthess and Gessner (1986) reported oscillations in the platelet counts of healthy subjects who did not exhibit bleeding symptoms. The data from three of these individuals showed significant cycling.
DISCUSSION AND CONCLUSIONS
Prehaps the most vexing statistical issue of this study is the assignment of the likelyhood of significance. Given only one of any of the 18 time series for which p 5 0.05, then the significance (relative to the possibility that the time series was generated by noise) is clear: it is the 71 value quoted in Table 1 . However, given the fact that we had multiple data sets in which we found significance @ 5 0.05) the question is "What significance level must be choosen to be sure that none of the detected cycling is, in fact, just noise?"
A simple example will suffice, and we consider the hematologically normal individuals first. Since we had data from four normals in which cycling was claimed, in order to make sure with a probability p _< 0.05 that none of the individuals platelet time series would be falsely classified as periodic we would have to take p < 0.05/4 = 0.0125 (the Bonferroni criteria, Snedecor and Cochran (1980) ). With this more rigorous criterion, all three of the normal individuals reported in Table I pass the test of statistically significant cycling at the 0.05 level. Period (days)
FIGURE 2 As in Figure 1 Gray and Kirk (1971) ; Gyori and Eller (1987) ; von Schulthess and Gessner (1986); Wichmann et al. (1979) l. Some of these models have considered only a simple thrombopoietin feedback [BClair and Mackey (1987) ; Gray and Kirk (1971) ; von Schulthess and Gessner (1986)l while others have been much more physiologically detailed ; Gyori and Eller (1987); Wichmann et al. (1979)J. von Schulthess and Gessner (1986) formulated their model to understand the platelet cycling in seven normal individuals (four women and three men) that their time series analysis revealed. Their analysis suggested that the normal platelet control system was biased close to a stability boundary and that this was the origin of the observed oscillatory platelet counts in some normal individuals. BClair and Mackey (1987) specifically considered cyclical thrombocytopenia. They speculated that elevations in the random destruction rate of platelets could give rise to the characteristic patterns observed in cyclical thrombocytopenia. Though modeling results based on this assumption yielded results qualitatively consistent with the clinical data, there is still much room for further elaboration of this problem.
The origin of the dynamics of cyclical thrombocytopenia is not clear. However, there is every reason to believe that this will soon resolve itself in the face of the determined investigations being carried out at a variety of levels. The range of actions of TPO (briefly detailed in Section 2.1) is hauntingly reminiscent of those of both G-CSF and EPO l. The broad outlines of the normal control of platelet production and its pathological derangement will probably be similar to those discovered for granulocyte regulation [Hearn et al. (1998) l and erythrocyte regulation [BClair et al. (1995) ; Mahaffy et al. (1998) l. Though the details of a viable model for the control of platelet production via TPO are unclear, it is clear that platelet production shares many qualitative similarities with the control of erythrocyte production. It would not be unexpected if a model for platelet regulation shared many features in common with models for erythrocyte regulation [Mahaffy et al. (1998) l.
